Skip to content

Evaluation of the feasibility, safety, and efficacy of active surveillance in the management of patients with very low risk papillary thyroid microcarcinoma: a prospective, observational study based on Chinese population

A real-world study for active surveillance in Chiese population with very low risk micropapillary thyroid cancer

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000032623
Enrollment
Unknown
Registered
2020-05-04
Start date
2020-05-01
Completion date
Unknown
Last updated
2020-05-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Papillary Thyroid Cancer

Interventions

Case series:Surveillance for disease progression, quality of life, and anxiety state

Sponsors

The First Affiliated Hospital of Kunming Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Be diagnosed as papillary thyroid cancer (PTC) or suspected PTC by fine needle aspiration biopsy (Bethesda V or VI categories); 2. Intrathyroidal unifocal PTC, which surrounded by >=2 mm normal thyroid parenchyma; 3. Tumor size =18 years old; 7. Normal thyroid stimulating hormone level by electrochemiluminescence assay; 8. Patients had no psychological, family, social or geographical constraints that affected protocol adherence and follow-up; 9. Patients volunteering to participate and signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with hashimotos disease or history; 2. Family history of thyroid cancer in immediate family member; 3. Previous cervical surgery history or other factors that may interfere with ultrasound examination (e.g. thyroiditis, lymphadenopathy, or, multifocal benign nodules); 4. With severe disease of cardiopulmonary, central nervous system disease, or other malignant tumor; 5. Mental disorder and cognition impairment that cannot correctly describe their feelings; 6. A history of alcohol, drug or substance abuse; 7. Expected duration of surveillance <3 months; 8. Patients or major family members who are unwilling to accept active surveillance protocol or have severe anxiety 9. For any other reason judged by the researcher as not suitable to participate in this study.

Design outcomes

Primary

MeasureTime frame
Cumulative rate of disease progression-free;Disease-specific survival;

Secondary

MeasureTime frame
The quality of life score;Hamilton anxiety score;

Countries

China

Contacts

Public ContactWen Liu

The First Affiliated Hospital of Kunming Medical University

dr.liuwen@foxmail.com+86 15587003317

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026